Latest Biotechnology News

Page 22 of 82
Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.
Ada Torres
Ada Torres
29 Jan 2026
Inhalerx Limited reported a $628,000 cash burn in the December quarter while securing substantial funding facilities to advance its clinical trials. The company’s cash position and financing arrangements suggest a runway extending over 80 quarters at current spending levels.
Ada Torres
Ada Torres
29 Jan 2026
Neurizon Therapeutics has locked in a $6 million cash rebate from the Australian Government’s R&D Tax Incentive, underpinning its upcoming HEALEY ALS Platform Trial with first patient dosing slated for early 2026.
Ada Torres
Ada Torres
29 Jan 2026
Immutep Limited has entered a strategic collaboration with Dr. Reddy’s, receiving a A$30 million upfront payment and potential milestones up to A$528 million, while reporting promising clinical progress across multiple cancer immunotherapy trials.
Ada Torres
Ada Torres
29 Jan 2026
Mesoblast Limited reported a 60% jump in Ryoncil sales to US$35 million for the December quarter, alongside securing a US$125 million credit facility that enhances its financial flexibility and supports ongoing clinical development.
Ada Torres
Ada Torres
29 Jan 2026
Syntara Limited has made significant strides in its clinical pipeline, launching new trials and receiving key regulatory designations, positioning 2026 as a pivotal year for the company.
Ada Torres
Ada Torres
29 Jan 2026
Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.
Ada Torres
Ada Torres
29 Jan 2026
Dimerix Limited has completed recruitment for its pivotal ACTION3 Phase 3 trial targeting a rare kidney disease, secured positive FDA feedback on trial endpoints, and reported a solid cash position of AU$38.5 million at the end of 2025.
Ada Torres
Ada Torres
29 Jan 2026
Cynata Therapeutics has completed enrolment in major clinical trials for osteoarthritis and acute graft versus host disease, with pivotal results expected in the second quarter of 2026. The company also strengthened its patent portfolio and secured additional funding to extend its operational runway.
Ada Torres
Ada Torres
29 Jan 2026
Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.
Ada Torres
Ada Torres
29 Jan 2026
Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.
Ada Torres
Ada Torres
29 Jan 2026
Microba Life Sciences reports a 90% year-on-year increase in core microbiome test volumes, driving a 123% rise in core testing revenue to $2.1 million, while advancing clinical adoption and cost efficiencies.
Ada Torres
Ada Torres
29 Jan 2026